有害事象報告詳細
| VAERS ID | 1340521 |
|---|---|
| 性別 | 不明 |
| 年齢 | |
| 州コード | IL |
| 製薬会社 | ファイザー |
| ロット番号 | |
| ワクチン接種回数 | |
| 接種日 | 2021-01-03 |
| 発生日 | 2021-05-03 |
| 状態 | 入院 重篤 |
症状
- SARS-CoV-2テスト(SARS-CoV-2 test)
- 新型コロナウイルス感染症(COVID-19)
- 薬が効かない(Drug ineffective)
罹患中の病気
持病
その他医療
以前のワクチン接種
アレルギー
臨床検査
Test Date: 20210503; Test Name: COVID-19 test; Test Result: Positive
症状詳細
COVID-19 confirmed by positive COVID-19 test; COVID-19 confirmed by positive COVID-19 test; This spontaneous report from a contactable nurse reporting same events under the same suspect product for 19 patients.
This is one of 19 reports.
An elderly patient of an unspecified gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 03Jan2021 (Batch/Lot number was not reported) at single dose for COVID-19 immunization.
The patient's medical history and concomitant medications were not reported.
Prior to vaccination, the patient was not diagnosed with COVID-19.
The patient experienced positive with COVID-19 on 03May2021.
It was reported that 19 residents in the long term care facility where the reporter work were fully vaccinated and are positive with COVID-19.
Some were not doing well at all.
The events was serious for being hospitalization, life threatening.
The events result in Emergency room/department or urgent care.
Since the vaccination, the patient had been tested for COVID-19 on 03May2021 with positive result.
The outcome of the events was unknown.
Information on the lot/batch number has been requested.
; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162B2 vaccine, cannot be excluded for the reported events of COVID-19 and suspected LOE.
There is limited information provided in this report.
This case will be reassessed once additional information is available.
The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events.
Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
,Linked Report(s) : US-PFIZER INC-2021548296 same reporter, vaccine and AE, different patient